0001636282-26-000117.txt : 20261002 0001636282-26-000117.hdr.sgml : 20261002 20261002212927 ACCESSION NUMBER: 0001636282-26-000117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260930 FILED AS OF DATE: 20261002 DATE AS OF CHANGE: 20261002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burrows Scott L CENTRAL INDEX KEY: 0001853327 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261438618 MAIL ADDRESS: STREET 1: C/O SPYRE THERAPEUTICS, INC. STREET 2: 221 CRESCENT STREET, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1790990964.xml FORM 4 X0609 4 2026-09-30 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001853327 Burrows Scott L false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 0 1 0 0 Chief Financial Officer 1 Common Stock 2026-09-30 4 M 0 17500 14.50 A 97262 D Common Stock 2026-09-30 4 S 0 17500 89.89 D 79762 D Common Stock 2026-10-01 4 M 0 7500 14.50 A 87262 D Common Stock 2026-10-01 4 S 0 600 89.07 D 86662 D Common Stock 2026-10-01 4 S 0 1500 90.27 D 85162 D Common Stock 2026-10-01 4 S 0 2100 91.92 D 83062 D Common Stock 2026-10-01 4 S 0 3071 92.95 D 79991 D Common Stock 2026-10-01 4 S 0 229 93.57 D 79762 D Stock Option (Right to Buy) 14.50 2026-09-30 4 M 0 17500 0 D 2033-09-01 Common Stock 17500 319857 D Stock Option (Right to Buy) 14.50 2026-10-01 4 M 0 7500 0 D 2033-09-01 Common Stock 7500 312357 D The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-10-02